Executive Summary
VIVITRO LABS INC. successfully achieved institution at the PTAB for its IPR against Patent No. 9237935, challenging claims related to prosthetic heart valve testing systems. The Board found a reasonable likelihood of success over Dynatek regarding certain limitations, despite preliminary rejections on other grounds.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in VIVITRO LABS INC. vs BIOMEDICAL DEVICE CONSULTANTS & LABORATORIES OF COLORADO, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Apple Inc.vsSmith Interface Technologies, LLC
The PTAB issued a Final Written Decision finding the claims patentable over the cited prior art. The Petitioner (Apple Inc.) failed to demonstrate that combining Ramos Paper, Ramos Video, and Ording would teach a Person of Ordinary Skill in the Art how to implement the claimed translucent virtual display layer widget overlaying image content.
Lenovo (United States) Inc. et al.vsIntellectual Ventures II
Lenovo challenges 7325140 in an IPR, arguing the claims are obvious over various combinations of prior art related to remote device management. The petitioner contends that allowance was based on low-level implementation details already disclosed in references like Neufeld and IPMI/Lawrence.
Quotient Technology, LLC et al.vsIntelligent Clearing Network Inc. et al.
The PTAB granted institution for Quotient Technology's IPR against Intelligent Clearing Network Inc.'s coupon redemption patent (9070133). The Board found a reasonable likelihood of success over Paul and Brown, despite rejecting the petitioner's narrow claim construction.
Giesecke+Devrient GmbH et al.vsLumenco, LLC
The PTAB denied institution of an IPR challenging Lumenco's anti-counterfeiting patent (10317691), finding the petitioner failed to show a reasonable likelihood of prevailing on obviousness grounds.
Merck Sharp & Dohme LLC et al.vsThe Johns Hopkins University
The PTAB found all 30 challenged claims unpatentable by anticipation (102) and obviousness (103). The Petitioner successfully argued that the MSI-H Study Record anticipates the claimed methods for treating non-colorectal MSI-H cancers.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.